WOMEN’S HEALTH (also see Cancer, Cardiovascular Disease, Diabetes, Health Services)

Division of Research Principal Investigator: Bruce Ettinger, MD
Primary Source of Funding: Eli Lilly Pharmaceuticals
Total Project Period: September 1999 – January 2004
Description: Title defines study.

Division of Research Principal Investigator: Bruce Ettinger, MD
Primary Source of Funding: Berlex Laboratories
Total Project Period: December 1999 – December 2002
Description: This study will test the ability of a quarter strength estradiol patch to prevent bone loss in women aged 60 and older.

Primary Source of Funding: Proctor & Gamble Pharmaceuticals, Inc.
Total Project Period: November 1996 – December 2001
Division of Research Principal Investigator: Bruce Ettinger, MD
Description: The major aim of this study is to determine whether continuation of hormone treatment is different between women who initiated therapy using a pill (Premarin) versus those who initiated therapy with a transdermal patch (Estraderm). A secondary aim of the study is to determine the rate of gynecologic procedures for abnormal bleeding in these two groups.

Primary Source of Funding: Kaiser Foundation Research Institute
Total Project Period: January 2001 – December 2003
Division of Research Principal Investigator: Carol Somkin, PhD
Description: This study will examine how women assess their personal risk of breast cancer versus the risks and benefits of participating in the Study of Tamoxifen and Raloxifene(STAR) Trial.

Division of Research Principal Investigator: Bruce Ettinger, MD
Primary Source of Funding: Eli Lilly & Company
Total Project Period: December 2002 – May 2003
Description: Telephone survey of 600 women hormone users to evaluate the impact of Women's Health Initiative information on their decision to continue.

Division of Research Principal Investigator: Barbara Sternfeld, PhD
Primary Source of Funding: National Institutes of Aging
Total Project Period: January 1999 – June 2002
Description: This study will examine the influence of physical activity on characteristics of the menstrual cycle, reproductive hormonal patterns, and hormone–related symptoms using three different data sets.

Primary Source of Funding: Merck & Company
Total Project Period: November 1998 – June 2001
Division of Research Principal Investigator: Bruce Ettinger, MD
Description: This study will determine if there is an increased risk of gastric and duodenal abnormalities among patients with osteoporotic fractures.

Primary Source of Funding: National Institute of Environmental Health Sciences
Total Project Period: January 2001 – June 2001
Division of Research Principal Investigator: Assiamira Ferrara, MD, PhD
Description: This study will provide the first intergenerational investigation of the relation of organochlorine exposure to reproductive performance and endocrine function in two generations of women.

Division of Research Principal Investigator: Bruce Ettinger, MD
Primary Source of Funding: Kaiser Foundation Research Institute
Total Project Period: January 2002 – December 2002
Description: This study will examine the impact of providing physicians with absolute fracture risk as well as bone density results. It uses a novel, Web-based, survey methodology with hypothetical cases.

Primary Source of Funding: Solvay Pharmaceuticals
Total Project Period: April 1998 – September 2001
Division of Research Principal Investigator: Bruce Ettinger, MD
Description: This study will evaluate safety and efficacy of hormone therapy composed of half-strength estrogen combined with every 6-month cycles of progestin.

Primary Source of Funding: National Heart, Lung, and Blood Institute
Total Project Period: September 1997 – August 2001
Division of Research Principal Investigator: Stephen Sidney, MD, MPH
Description: This study will determine: 1) the relative and attributable risk of venous thromboembolic disease (deep venous thrombosis and pulmonary embolism) in current users of low-dose (<50 micrograms estrogen) oral contraceptive preparations, and 2) the prevalence of the factor V Leiden mutation in cases and controls and the relative and attributable risk of venous thromboembolic disease associated with its presence.

Division of Research Principal Investigator: Elisabeth Gruskin, DrPH
Primary Source of Funding: Bristol-Myers Squibb Company
Total Project Period: August 2000 – August 2002
Description: The STAMP Study is a clinical trial looking at the side effect profiles of antidepressants in older women with an emphasis on sexual side effects and sleep.

Primary Source of Funding: Novartis Pharmacy Corporation
Total Project Period: August 1996 – December 2001
Division of Research Principal Investigator: Bruce Ettinger, MD
Description: The purpose of this study is to determine the tolerability, compliance with patients’ instructions regarding use, and continuation of Alendronate therapy among women initiating this osteoporosis treatment. Also, to evaluate incidence of acid-related disorders and symptoms among women using Alendronate.